Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals Inc (NQ: LBPH )

35.79 +0.69 (+1.95%)
Streaming Delayed Price Updated: 9:48 AM EDT, Aug 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longboard Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Recap: Longboard Pharmaceuticals Q4 Earnings
Via Benzinga
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Looking Into Longboard Pharmaceuticals's Recent Short Interest
Via Benzinga
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
These three small-cap stocks could deliver hefty returns if the central bank cuts rates. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Top 3 Health Care Stocks That May Crash This Quarter
Via Benzinga
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024
LBPH stock results show that Longboard Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher
You might say that this biotech stock is magnificent. 
Via The Motley Fool
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. 
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Longboard Pharmaceuticals, Inc.
Via Business Wire
This biotech stock has surged over 300% this week
Shares of Longboard Pharmaceuticals (NASDAQ: LBPH) have sky-rocketed higher this week, up over 300% thanks to breaking news 
Via MarketBeat
Jim Cramer: This Energy Firm Has 'Good Growth, Good Yield' But As For IonQ? Ixnay
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Equitrans Midstream Corporation (NYSE: ETRN) is very solid. "Good growth, good yield. 
Via Benzinga
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.